Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
Enliven Therapeutics (Nasdaq: ELVN) has announced it will present five posters at the 2025 AACR Annual Meeting in Chicago from April 25-30, 2025. The presentations will showcase their pipeline of small molecule therapeutics, including:
- ELVN-002: A selective HER2 inhibitor with potential enhanced efficacy in combination with antibody-drug conjugates
- ELVN-001: A selective ABL1 tyrosine kinase inhibitor for chronic myeloid leukemia treatment
- ELV-3111: A type 1 pan-RAF inhibitor for NRAS and BRAF mutant cancers
The presentations will cover pharmacokinetics, drug resistance mechanisms, and combination therapy approaches. All posters will be presented on April 29, 2025, across different sessions and locations at the conference.
Enliven Therapeutics (Nasdaq: ELVN) ha annunciato che presenterà cinque poster al 2025 AACR Annual Meeting a Chicago dal 25 al 30 aprile 2025. Le presentazioni metteranno in evidenza il loro portafoglio di terapie a piccole molecole, tra cui:
- ELVN-002: Un inibitore selettivo di HER2 con potenziale efficacia potenziata in combinazione con coniugati anticorpo-farmaco
- ELVN-001: Un inibitore selettivo della tirosina chinasi ABL1 per il trattamento della leucemia mieloide cronica
- ELV-3111: Un inibitore pan-RAF di tipo 1 per i tumori mutati NRAS e BRAF
Le presentazioni copriranno la farmacocinetica, i meccanismi di resistenza ai farmaci e gli approcci alla terapia combinata. Tutti i poster saranno presentati il 29 aprile 2025, in diverse sessioni e location durante la conferenza.
Enliven Therapeutics (Nasdaq: ELVN) ha anunciado que presentará cinco carteles en la Reunión Anual AACR 2025 en Chicago del 25 al 30 de abril de 2025. Las presentaciones destacarán su cartera de terapias de pequeñas moléculas, incluyendo:
- ELVN-002: Un inhibidor selectivo de HER2 con potencial de eficacia mejorada en combinación con conjugados anticuerpo-fármaco
- ELVN-001: Un inhibidor selectivo de la tirosina quinasa ABL1 para el tratamiento de la leucemia mieloide crónica
- ELV-3111: Un inhibidor pan-RAF de tipo 1 para cánceres mutantes de NRAS y BRAF
Las presentaciones cubrirán la farmacocinética, los mecanismos de resistencia a los fármacos y los enfoques de terapia combinada. Todos los carteles se presentarán el 29 de abril de 2025, en diferentes sesiones y ubicaciones durante la conferencia.
Enliven Therapeutics (Nasdaq: ELVN)는 2025년 4월 25일부터 30일까지 시카고에서 열리는 2025 AACR 연례 회의에서 다섯 개의 포스터를 발표할 것이라고 발표했습니다. 발표에서는 다음과 같은 소분자 치료제 파이프라인을 소개할 예정입니다:
- ELVN-002: 항체-약물 접합체와의 병용에서 잠재적으로 향상된 효능을 가진 선택적 HER2 억제제
- ELVN-001: 만성 골수성 백혈병 치료를 위한 선택적 ABL1 티로신 키나제 억제제
- ELV-3111: NRAS 및 BRAF 돌연변이 암을 위한 1형 pan-RAF 억제제
발표에서는 약물 동태학, 약물 내성 메커니즘 및 병용 요법 접근법을 다룰 것입니다. 모든 포스터는 2025년 4월 29일 회의의 다양한 세션과 장소에서 발표될 예정입니다.
Enliven Therapeutics (Nasdaq: ELVN) a annoncé qu'elle présentera cinq affiches lors de la Réunion Annuelle AACR 2025 à Chicago du 25 au 30 avril 2025. Les présentations mettront en avant leur portefeuille de thérapies à petites molécules, notamment :
- ELVN-002: Un inhibiteur sélectif de HER2 avec une efficacité potentiellement améliorée en combinaison avec des conjugués anticorps-médicament
- ELVN-001: Un inhibiteur sélectif de la tyrosine kinase ABL1 pour le traitement de la leucémie myéloïde chronique
- ELV-3111: Un inhibiteur pan-RAF de type 1 pour les cancers mutés NRAS et BRAF
Les présentations couvriront la pharmacocinétique, les mécanismes de résistance aux médicaments et les approches de thérapie combinée. Tous les affiches seront présentées le 29 avril 2025, lors de différentes sessions et à différents endroits de la conférence.
Enliven Therapeutics (Nasdaq: ELVN) hat angekündigt, dass es fünf Poster auf dem 2025 AACR Annual Meeting in Chicago vom 25. bis 30. April 2025 präsentieren wird. Die Präsentationen werden ihr Portfolio an kleinen Molekültherapeutika vorstellen, darunter:
- ELVN-002: Ein selektiver HER2-Inhibitor mit potenziell verbesserter Wirksamkeit in Kombination mit Antikörper-Wirkstoff-Konjugaten
- ELVN-001: Ein selektiver ABL1-Tyrosinkinase-Inhibitor zur Behandlung der chronischen myeloischen Leukämie
- ELV-3111: Ein Typ-1-Pan-RAF-Inhibitor für NRAS- und BRAF-mutierte Krebserkrankungen
Die Präsentationen werden die Pharmakokinetik, Mechanismen der Arzneimittelresistenz und Ansätze zur Kombinationstherapie abdecken. Alle Poster werden am 29. April 2025 in verschiedenen Sitzungen und Orten auf der Konferenz präsentiert.
- Pipeline advancement with three distinct therapeutic candidates in development
- ELVN-002 shows potential for enhanced combination therapy in HER2 treatment
- ELV-3111 demonstrates ability to address BRAF inhibitor resistance
- None.
Poster Presentation Details
Abstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates
Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT
Session: Targeted Therapies and Combinations 2
Location: Poster Section 34
Abstract 4361 – Development and application of a mechanistic pharmacokinetic pharmacodynamic (PKPD) model to predict anti-chronic myeloid leukemia (CML) effects of tyrosine kinase inhibitors
Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT
Session: Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics
Location: Poster Section 20
Abstract LB295 – ELV-3111, a type 1 pan-RAF inhibitor, that safely combines with MEK inhibitors for enhanced anti-tumor activity in NRAS and BRAF mutant cancers including the most common mechanisms of BRAF inhibitor clinical resistance
Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Location: Poster Section 52
Abstract LB294 – Mechanism of tumor-selective inhibition of dimeric RAF by a Type 1 RAF inhibitor
Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Location: Poster Section 52
Abstract 5515 – ELVN-001, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia alone or in combination with asciminib
Date/Time: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. CDT
Session: Drug Resistance in Molecular Targeted Therapies 3
Location: Poster Section 17
Abstracts are currently available on the AACR website. Following the presentations, copies will be available on the "Program Presentations & Publications" section of the Company's website at www.enliventherapeutics.com.
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder,
View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting-302419011.html
SOURCE Enliven Therapeutics, Inc.